Spyropoulos AC, Lipardi C, Xu J. et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost 2019; 25: 1076029619886022 (e-pub ahead of print) DOI: 10.1177/1076029619886022.
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.